Valuation: Outlook Therapeutics, Inc.

Market Cap 16Cr 13Cr 13Cr 12Cr 22Cr 1.49TCr 22Cr 151.66Cr 58Cr 755.08Cr 58Cr 57Cr 2.4TCr P/E 2026 *
-1.1x
P/E 2027 * -2.94x
Enterprise Value 16Cr 13Cr 13Cr 12Cr 22Cr 1.49TCr 22Cr 151.66Cr 58Cr 755.08Cr 58Cr 57Cr 2.4TCr EV / Sales 2026 *
227x
EV / Sales 2027 * 3.52x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day-3.35%
1 week-4.29%
Current month+0.71%
1 month-15.67%
3 months-47.71%
6 months+61.90%
Current year-59.63%
1 week 0.62
Extreme 0.621
0.68
1 month 0.59
Extreme 0.59
0.8
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
18
5 years 0.16
Extreme 0.1611
48.8
10 years 0.16
Extreme 0.1611
806.4
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Director of Finance/CFO 59 01/09/2026
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Director/Board Member 50 31/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Free

Chief Financial Officer

5,00,000 0.3122%
14/08/26 Buy

Chief Executive Officer

2,02,020 0.0832%
14/08/26 Buy

Chief Executive Officer

3,03,030 0.1249%
Change 5-day change 1-year change 3-year change Capi.($)
-3.35%-4.29%-38.66%-85.97% 16Cr
-0.67%-4.71%-3.18%+6.51% 4.56TCr
+0.66%-2.34%+340.62%+530.14% 4.4TCr
+1.49%-0.78%+41.90%+24.75% 4.37TCr
+2.11%-1.24%+9.09%+78.25% 4.02TCr
+0.34%-4.03%+9.34%+38.90% 3.19TCr
+0.53%-2.08% - - 1.74TCr
+1.34%+0.70%+21.35%+112.62% 1.66TCr
+0.55%+1.91%+15.03%+31.07% 1.45TCr
-1.85%-5.33%+78.63%+31.45% 1.3TCr
Average +0.12%-1.99%+52.68%+85.30% 2.67TCr
Weighted average by Cap. +0.65%-2.01%+75.76%+127.33%

Financials

2026 *2027 *
Net sales 7L 6L 6L 5L 10L 6.54Cr 10L 66.67L 25.69L 3.32Cr 25.64L 25.08L 11Cr 4.41Cr 3.82Cr 3.6Cr 3.27Cr 6.13Cr 422.4Cr 6.18Cr 43Cr 17Cr 214.28Cr 17Cr 16Cr 681.24Cr
Net income -6.51Cr -5.64Cr -5.32Cr -4.83Cr -9.06Cr -623.96Cr -9.13Cr -64Cr -24Cr -316.53Cr -24Cr -24Cr -1.01TCr -4.44Cr -3.85Cr -3.63Cr -3.3Cr -6.18Cr -425.88Cr -6.23Cr -43Cr -17Cr -216.05Cr -17Cr -16Cr -686.85Cr
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
14/26/14 $0.6379 -3.35% 28,48,345
11/26/11 $0.6600 -0.18% 33,34,025
10/26/10 $0.6612 +2.69% 31,11,958
09/26/09 $0.6439 +0.53% 26,75,900
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.6379USD
Average target price
5.025USD
Spread / Average Target
+687.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!